Ambrx Raises $23.4M

San Diego-based Ambrx has raised $23.4M for its protein-based medicines. The preferred stock placement included participation by new firms Maverick Capital, CMEA Ventures, Twilight Venture Partners and Alexandria Real Estate Equities. Existing investors Tavistock Life Sciences, 5AM Ventures, Versant Ventures and Aravis Ventures also participated. The firm said that David Singer of Maverick will join the company's board as part of the funding. More information »